Study on Immunogenicity, Reactogenicity and Safety of the VAC Δ6 Vaccine in Volunteers Aged 18-60 Years

Conditions:   Smallpox;   Monkeypox;   Cowpox;   Vaccinia Virus Infection Interventions:   Biological: VAC∆6 vaccine (10⁷ PFU);   Biological: VAC∆6 vaccine (10⁶ PFU);   Biological: Live Smallpox Vaccine;   Other: Placebo (Sodium chloride bufus, 0.9%) Sponsor:   Federal Budgetary Research Institution State Research Center of Virology and Biotechnology " Vector " Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials